Latest news with #Cognitive
Int'l Business Times
2 days ago
- Health
- Int'l Business Times
From Research to Real Life: Transforming the Opportunity for Early Detection of Alzheimer's Disease with i-Function
When healthcare entrepreneur Peter Kallestrup co-founded i-Function®, he set out with a clear mission: to take powerful innovations confined to academic research and make them widely accessible tools for real-world cognitive health improvements. "What if we could leverage all that incredible research being done in universities and make it available so that it can benefit people in the real world?" Kallestrup asked. That question became the foundation of a company designed not just to innovate, but to democratize access to cognitive care. i-Function ® is led by Kallestrup alongside two highly regarded academics, Dr. Philip D. Harvey , an expert in mental health and cognition, and Dr. Sarah J. Czaja , a leading authority in functional skills and aging research. Together, they have played a significant role in developing two flagship products: LASSI-D® and FUNSAT®. The former is a digital cognitive assessment tool; the latter, a digital functional skills assessment and training platform. While both serve different purposes, they both play a role in the process of assessing and supporting cognitive health. LASSI-D ™ is the company's most recent innovation, a 15-minute digital cognitive assessment designed to detect the earliest stages of Mild Cognitive Impairment (MCI) and asymptomatic older adults with preclinical Alzheimer's disease. Dr. Sara J. Czaja explains, "It's like a Cardiac Stress Test for the brain. In just 15 minutes, we can tell with high probability whether your cognitive aging is likely normal or whether something else might be going on." The test is completely self-guided, with a human avatar serving the role of a human testing technician, leading users through the process privately and comfortably on most smart devices. The value of early detection can't be overstated. According to research published in The Lancet , up to 40% of the risk of developing Alzheimer's can be mitigated through mid-late life lifestyle changes if the warning signs are caught early. "What would it be worth to have two more years with your mom, dad, or spouse with normal cognitive and functional abilities?" Dr. Harvey asks. "It's priceless. That's what we aim to offer, more time, more clarity, more hope." FUNSAT ™, the company's original product, addresses functional skills: the day-to-day tasks that many with cognitive impairments struggle to perform. From managing medications to using online banking or navigating a phone voice menu, the tool helps individuals regain or build these critical capabilities. "It's not just about remembering or understanding something, it's about utilizing those cognitive skills in real life," says Dr. Harvey. "If we identify someone with early MCI using LASSI-D™, then FUNSAT™ becomes one of the suggested practical next steps in helping people live independently for longer." While i-Function's tools have applications across many domains, clinical research, mental health treatment, rehabilitation, and aging care, their business model is currently B2B. Memory clinics, assisted living facilities, concierge medical practices, state mental health organizations, and pharma are among their key clients. "We are solving two problems," Kallestrup explains. "First, we give providers a fast, affordable, documented way to screen for early cognitive issues. Second, we offer an actionable path forward. That combination is rare." The company has already seen early traction. FUNSAT™ is being used in several state-run mental health facilities and in clinical trials, and LASSI-D™ has entered its first wave of clinical adoption. The rollout is ongoing, with strong interest from both specialists and academic research centers alike. "Doctors don't always have time or the appropriate tools to assess cognitive health thoroughly or early enough, and many aren't necessarily comfortable making this assessment independently," Kallestrup notes. "With LASSI-D, they can run a fast, highly accurate screening with instant results and recommendations while patients wait. That's powerful." Importantly, i-Function® is not focused on elite clinics or high-income users. "We are not building expensive tools for the wealthy," Peter Kallestrup, CEO of i-Function®, emphasizes. "This needs to be accessible to millions. Affordability is core to our mission." This ethos is one reason i-Function® in-licenses tools from leading research universities, then develops them into scalable, tech-enabled platforms. It's not about reinventing the science, it's about amplifying it. That model has also gathered serious attention. The company's research has been supported by several highly competitive NIH grants. "Everything we do is backed by peer-reviewed science," Kallestrup says. "We have had the privilege of presenting on national stages, and last year we were cited in the National Institute of Aging annual report. But the most important recognition is seeing how our tools can change lives." Looking ahead, i-Function® plans to continue to develop its current solutions as well as broaden its portfolio with new tools focused on the broad domain of cognitive health. The goal remains consistent: find transformative but underutilized academic discoveries and bring them to the people who need them most. For Kallestrup, it's a matter of urgency as much as innovation. "If you knew you were at risk of Alzheimer's, wouldn't you want to act now? Wouldn't you want the chance to intervene while it still matters?" he says. "That's the opportunity we are giving people. And we are just getting started."
Yahoo
21-05-2025
- Business
- Yahoo
Neurogen Biomarking Announces Partnership with Aranscia
Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen's Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and Alzheimer's Dementia CHICAGO and HOUSTON, May 21, 2025 /PRNewswire/ -- Neurogen Biomarking, the world's first ecosystem for memory loss with end-to-end patient support, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership in which Aranscia's technical and laboratory resources will help to deliver clinical insights and HIPAA-compliant connectivity for the Neurogen Biomarking ecosystem. Under this partnership, AccessDx Laboratory, an Aranscia company, will provide Neurogen with technical, operational, and analytical support resources for its blood-based biomarker test that measures phosphorylated tau (p-tau) 217, a specific marker for Alzheimer's disease pathology. AccessDx Laboratory is a CAP-accredited, CLIA-certified, NYSDOH-approved diagnostic laboratory focused on both the development and scaling of novel diagnostic programs. In addition, 2bPrecise, another Aranscia company, will provide Neurogen with software-based, EMR-agnostic clinical workflow utilities that help to securely integrate Neurogen's diagnostic results and programmatic insights across the Neurogen ecosystem and within a wide range of clinical care settings. 2bPrecise's HIPAA-compliant software solutions currently support thousands of discrete client groups, including leading health systems, municipalities, ACOs, and multi-provider organizations. "Neurogen's driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a scientifically and clinically controlled ecosystem while also guiding them every step of the way in their brain health journey," said Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking. "Aranscia's proven experience in supporting a wide range of complex diagnostic and clinical workflows, combined with their expertise in enabling innovative and secure end-to-end personalized diagnostic programs, makes them the ideal partner to help us both achieve our objectives and position for scale." Neurogen's platform is the first patient-initiated system designed to shift the paradigm of early detection of Alzheimer's disease (AD) through improved access to innovative blood biomarker testing and AI-enhanced digital and cognitive assessments. Board-certified neurologists will support eligible Neurogen patients every step of the way via telehealth, providing follow-up care if indicated and accelerating access to expert cognitive care - delivered in weeks rather than the months-long wait times typically seen in traditional neurology care. "We're proud to partner with Neurogen on its mission to accelerate early detection and interventionist care in the fight against Alzheimer's disease, which has become all too personal for millions of Americans and their families," said Bryon Cipriani, CEO of Aranscia. "This partnership builds upon the foundational efforts of AccessDx Laboratory and 2bPrecise in helping to democratize access to personalized and precision care for all, and in ways that proactively and positively impacts the lives of the patients we help to serve." Aranscia joins Neurogen's collaborators Linus Health, which is providing the cutting-edge digital cognitive assessments for patients with memory concerns on the Neurogen Biomarking platform; Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection; and NeuroX, a venture of American TelePhysicians, to provide virtual neurology services that help guide the patient journey on its brain health care ecosystem. The platform will be widely available in mid-2025 for anyone with eligible memory and thinking concerns. Approximately 7 million Americans aged 65 and older were living with Alzheimer's dementia in 2024. It is estimated that 40% of Americans age 65+ experience memory impairment, affecting around 16 million people. Only 8% of Americans living with mild cognitive impairment receive a diagnosis, leaving 92% undiagnosed. The process of developing Alzheimer's disease is slow, with 15-20 years before the onset of Mild Cognitive Impairment (MCI). MCI precedes Alzheimer's disease by many years. About Neurogen BiomarkingNeurogen Biomarking is dedicated to supporting early detection of Alzheimer's disease and Mild Cognitive Impairment. Founded by award-winning neurologist, Dr. Rany Aburashed and guided by world-renowned brain health experts, Neurogen is on a mission to empower anyone with thinking and memory concerns with the tools, education, and motivation needed to access advanced, personalized care of patients with Alzheimer's disease – and a future with more in it. To learn more visit or follow us on LinkedIn. About Aranscia Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia's portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit Media Contacts:Neurogen Biomarking395551@ Aranscia 395551@ View original content to download multimedia: SOURCE Aranscia Sign in to access your portfolio
Yahoo
06-03-2025
- Automotive
- Yahoo
Nexus Cognitive Personnel Achieves Catena-X Certification, Driving the Future of Data Collaboration in Automotive
With this certification, Nexus Cognitive strengthens its position as a trusted partner for automotive suppliers and OEMs, delivering AI-driven data integration, governance, and interoperability solutions to accelerate digital transformation and supply chain innovation. ATLANTA, GEORGIA / / March 6, 2025 / Nexus Cognitive, a leader in enterprise Data & AI solutions, has officially been certified as a Catena-X Qualified Advisor. This milestone solidifies Nexus Cognitive's position as a trusted partner in data-driven collaboration and digital transformation within the automotive supply chain ecosystem. As the automotive industry undergoes a fundamental shift toward secure, standardized, and sustainable data sharing, Nexus Cognitive is at the forefront, enabling OEMs, suppliers, and logistics providers to seamlessly integrate into the Catena-X network. With expertise in data interoperability, AI-driven insights, and sustainability-driven analytics, the company empowers businesses to optimize supply chain performance, meet regulatory demands, and drive operational efficiency. Key Benefits of Nexus Cognitive's Catena-X Certification: Unmatched Competitive Edge - Establishes trusted leadership in security, traceability, and sustainability across the automotive supply chain. Industry Leadership & Compliance - Demonstrates deep expertise in Catena-X standards, protocols, and interoperability, ensuring businesses align with global digital transformation efforts. Accelerated Business Growth - Empowers OEMs and suppliers to onboard seamlessly, leveraging Nexus Cognitive's expertise to navigate Catena-X adoption with precision. AI-Powered Data Architecture - Enables real-time, AI-driven insights across logistics, manufacturing, and sustainability initiatives. Sustainability & ESG-Driven Innovation - Provides critical CO2 footprint tracking, circular economy insights, and compliance solutions, ensuring businesses meet evolving global regulatory standards. Anu Jain, CEO of Nexus Cognitive, on the Future of Automotive Data Innovation "Catena-X is not just an initiative-it's a fundamental shift in how the automotive industry operates. This is the future. And we're leading the Cognitive's certification cements our role as the go-to partner for companies serious about winning in this new era. If you're not leveraging Catena-X to its full potential, you're already behind. We're here to change that." Rohit Belgal on Nexus Cognitive's Data & AI Innovation in Automotive "As the Data & AI Lead at Nexus Cognitive, I've spent my career focused on how cutting-edge data architectures and AI-driven solutions can transform industries at scale. Catena-X is a game changer for automotive, and this certification allows us to drive real impact-helping OEMs and suppliers create more agile, intelligent, and sustainable supply chains," said Rohit Belgal, Managing Director for Data and AI at Nexus Cognitive. Expanding the Vision: The Next Step for Nexus Cognitive in Catena-X With this certification, Nexus Cognitive is poised to launch a SaaS solution package that goes beyond advisory services to enable seamless data exchange and collaboration across the automotive value chain. This upcoming offering will deliver scalable, automated, and AI-powered data-sharing solutions to accelerate digital transformation, sustainability initiatives, and supply chain intelligence for the automotive sector. For companies ready to unlock trusted, data-driven business outcomes at speed and scale-with less risk and lower costs, Nexus Cognitive is the force redefining the game. For more information, visit Contact Information Anu Jain CEO, Nexus Cognitiveanu@ SOURCE: Nexus Cognitive View the original press release on ACCESS Newswire
